Article Information
History
- April 28, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Xuan Liu1,#,
- Xiaopeng Zhang1,#,
- Yongjiu Xiao2,6,#,
- Ting Gao1,#,
- Guangfei Wang1,#,
- Zhongyi Wang1,6,
- Zhang Zhang1,
- Yong Hu1,
- Qincai Dong1,
- Songtao Zhao3,6,
- Li Yu4,6,
- Shuwei Zhang1,
- Hongzhen Li5,
- Kaitong Li5,
- Wei Chen1,
- Xiuwu Bian3,6,*,
- Qing Mao3,6,* and
- Cheng Cao1,*
- 1Beijing Institute of Biotechnology, Beijing 100850, China
- 2The 940th Hospital of the People’s Liberation Army, Lanzhou, Ganshu 30070, China
- 3First Affiliated Hospital, Army Medical University, Chongqing 400038, China
- 4Department of Critical Care Medicine, the 969th Hospital of Chinese People’s Liberation Army Joint Logistics Support Force, Hohhot, Neimenggu 010051, China
- 5Beijing Key Laboratory of Bio-products Safety Assessment, Joinn Laboratories (China) Co. Ltd. Beijing 100176, China
- 6Wuhan Huoshenshan Hospital, Wuhan, Hubei 430100, China
- ↵*Correspondence to: Xiuwu Bian (Phone: +86 137 0837 3857; E-mail: bianxiuwu{at}263.net), Qing Mao (Phone: +86 135 9418 0020; E-mail: qingmao{at}tmmu.edu.cn), Cheng Cao (Phone: +86-10-66931932; E-mail: caoc{at}nic.bmi.ac.cn)
↵# These authors contributed equally
Posted April 28, 2020.
Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment
